Research Pipeline

Molecule Indication MoA/Class
Pre-Clinical Phase 1 Phase 2 a Phase 2 b Phase 3 Approval
GBR 1302 HER2 positive cancers such as breast Cancer, gastric cancer & ovarian Cancer HER2xCD3 (bispecific mAb)
+
Oncology
GBR 1342 Multiple myeloma CD38xCD3 (bispecific mAb)
+
Oncology
GBR 1372 Colorectal Cancer EGFRxCD3 (bispecific mAb)
+
Oncology
GBR 8383 Multiple Cancers OX40R Agonist
Oncology
GBR 830 Autoimmune disease OX40 Antagonist (mAb)
+
Dermatology
GRC 388XX COPD, IPF Undisclosed
Respiratory
GSP 301 Allergic Rhinitis Steroid + AH
Respiratory
GSP 304 COPD LAMA
Respiratory
GBR 310 Asthma, CIU Biosimilar
Respiratory
GRC 27864 Chronic pain mPGES-1 Inhibitor
+
Pain

About Us

Leading, integrated, global, research-led organization. Words which define us and our vision to discover a healthier future
Know More